Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 2. Computational titration and pH effects in molecular models of neuraminidase-inhibitor complexes.

One factor that can strongly influence predicted free energy of binding is the ionization state of functional groups on the ligands and at the binding site at which calculations are performed. This analysis is seldom performed except in very detailed computational simulations. In this work, we address the issues of (i) modeling the complexity resulting from the different ionization states of ligand and protein residues involved in binding, (ii) if, and how, computational methods can evaluate the pH dependence of ligand inhibition constants, and (iii) how to score the protonation-dependent models. We developed a new and fairly rapid protocol called "computational titration" that enables parallel modeling of multiple ionization ensembles for each distinct protonation level. Models for possible protonation combinations for site/ligand ionizable groups are built, and the free energy of interaction for each of them is quantified by the HINT (Hydropathic INTeractions) software. We applied this procedure to the evaluation of the binding affinity of nine inhibitors (six derived from 2,3-didehydro-2-deoxy-N-acetylneuraminic acid, DANA) of influenza virus neuraminidase (NA), a surface glycoprotein essential for virus replication and thus a pharmaceutically relevant target for the design of anti-influenza drugs. The three-dimensional structures of the NA enzyme-inhibitor complexes indicate considerable complexity as the ligand-protein recognition site contains several ionizable moieties. Each computational titration experiment reveals a peak HINT score as a function of added protons. This maximum HINT score indicates the optimum pH (or the optimum protonation state of each inhibitor-protein binding site) for binding. The pH at which inhibition is measured and/or crystals were grown and analyzed can vary from this optimum. A protonation model is proposed for each ligand that reconciles the experimental complex structure with measured inhibition and the free energy of binding. Computational titration methods allow us to analyze the effect of pH in silico and may be helpful in improving ligand binding free energy prediction when protonation or deprotonation of the residues or ligand functional groups at the binding site might be significant.

[1]  J. Montgomery,et al.  Protonation of methotrexate bound to the catalytic site of dihydrofolate reductase from lactobacillus casei , 1981 .

[2]  B. Honig,et al.  Calculation of electrostatic potentials in an enzyme active site , 1987, Nature.

[3]  William L. Jorgensen,et al.  Free energy calculations: a breakthrough for modeling organic chemistry in solution , 1989 .

[4]  W G Laver,et al.  Structures of aromatic inhibitors of influenza virus neuraminidase. , 1995, Biochemistry.

[5]  P. Colman,et al.  The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor , 1992, Proteins.

[6]  I. Miller,et al.  Zanamivir: a review of clinical safety. , 1999, Drug safety.

[7]  J. Varghese,et al.  Development of neuraminidase inhibitors as anti‐influenza virus drugs , 1999 .

[8]  J. C. Dyason,et al.  A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs. , 1996, Journal of medicinal chemistry.

[9]  Brian J Smith,et al.  Structural studies of the resistance of influenza virus neuramindase to inhibitors. , 2002, Journal of medicinal chemistry.

[10]  G. Air,et al.  Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding , 1995, Journal of virology.

[11]  G. Flynn Substituent Constants for Correlation Analysis in Chemistry and Biology. , 1980 .

[12]  Peter R. Andrews,et al.  Functional groups, drug-receptor interactions and drug design , 1986 .

[13]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[14]  G E Kellogg,et al.  Computational methodology for estimating changes in free energies of biomolecular association upon mutation. The importance of bound water in dimer-tetramer assembly for beta 37 mutant hemoglobins. , 2000, Biochemistry.

[15]  J. Mccammon,et al.  On the evaluation and optimization of protein X‐ray structures for pKa calculations , 2003, Protein science : a publication of the Protein Society.

[16]  Mark von Itzstein,et al.  A structural and energetics analysis of the binding of a series of N-acetylneuraminic-acid-based inhibitors to influenza virus sialidase , 1996, J. Comput. Aided Mol. Des..

[17]  G E Kellogg,et al.  Computationally accessible method for estimating free energy changes resulting from site‐specific mutations of biomolecules: Systematic model building and structural/hydropathic analysis of deoxy and oxy hemoglobins , 2001, Proteins.

[18]  G. Klebe,et al.  Approaches to the Description and Prediction of the Binding Affinity of Small-Molecule Ligands to Macromolecular Receptors , 2002 .

[19]  M. Gilson,et al.  Computing ionization states of proteins with a detailed charge model , 1996, J. Comput. Chem..

[20]  J. Åqvist,et al.  Ligand binding affinities from MD simulations. , 2002, Accounts of chemical research.

[21]  A. Simas,et al.  Importance of tautomers in the chemical behavior of tetracyclinesdagger. , 1999, Journal of pharmaceutical sciences.

[22]  Themis Lazaridis,et al.  Binding Affinity and Specificity from Computational Studies , 2002 .

[23]  Julian Tirado-Rives,et al.  Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations. , 2002, Journal of medicinal chemistry.

[24]  G. Air,et al.  Potent inhibition of influenza sialidase by a benzoic acid containing a 2-pyrrolidinone substituent. , 1999, Journal of medicinal chemistry.

[25]  T. K. Carne,et al.  The origin of multiply sigmoid curves of pH-dependence. The partitioning of groups among titration pK values. , 1991, Biochemical Journal.

[26]  Michael K. Gilson,et al.  The determinants of pK(a)s in proteins , 1996 .

[27]  M G Ford,et al.  Binding constants of neuraminidase inhibitors: An investigation of the linear interaction energy method. , 1999, Journal of medicinal chemistry.

[28]  Glen E. Kellogg,et al.  Hydrophobicity: is LogPo/w more than the sum of its parts? , 2000 .

[29]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[30]  W G Laver,et al.  A sialic acid-derived phosphonate analog inhibits different strains of influenza virus neuraminidase with different efficiencies. , 1995, Journal of molecular biology.

[31]  W G Laver,et al.  Guanidinobenzoic acid inhibitors of influenza virus neuraminidase. , 1997, Journal of molecular biology.

[32]  P. Colman Influenza virus neuraminidase: Structure, antibodies, and inhibitors , 1994, Protein science : a publication of the Protein Society.

[33]  G E Kellogg,et al.  Hydropathic analysis of the non-covalent interactions between molecular subunits of structurally characterized hemoglobins. , 1997, Journal of molecular biology.

[34]  M. Gilson,et al.  Prediction of pH-dependent properties of proteins. , 1994, Journal of molecular biology.

[35]  Ajay,et al.  Computational methods to predict binding free energy in ligand-receptor complexes. , 1995, Journal of medicinal chemistry.

[36]  G. Kellogg,et al.  Which aminoglycoside ring is most important for binding? A hydropathic analysis of gentamicin, paromomycin, and analogues. , 2001, Bioorganic & medicinal chemistry letters.

[37]  P. Goodford A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[38]  G. Air,et al.  The neuraminidase of influenza virus , 1989, Proteins.

[39]  G. Air,et al.  Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction. , 1995, Journal of medicinal chemistry.

[40]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[41]  J. Aqvist,et al.  A new method for predicting binding affinity in computer-aided drug design. , 1994, Protein engineering.

[42]  G. Air,et al.  A strategy for theoretical binding constant, Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase , 1995, Proteins.

[43]  E. Knapp,et al.  Electrostatic models for computing protonation and redox equilibria in proteins , 1999, European Biophysics Journal.

[44]  G. Ullmann,et al.  Effects of pH on protein association: modification of the proton-linkage model and experimental verification of the modified model in the case of cytochrome c and plastocyanin. , 2001, Journal of the American Chemical Society.

[45]  Anna Marabotti,et al.  Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 1. Models without explicit constrained water. , 2002, Journal of medicinal chemistry.

[46]  M. Gilson,et al.  The determinants of pKas in proteins. , 1996, Biochemistry.

[47]  R. Wade,et al.  Comparative binding energy (COMBINE) analysis of influenza neuraminidase-inhibitor complexes. , 2001, Journal of medicinal chemistry.

[48]  J. N. Varghese,et al.  Structure of the catalytic and antigenic sites in influenza virus neuraminidase , 1983, Nature.

[49]  G. Air,et al.  Site-directed mutation of the active site of influenza neuraminidase and implications for the catalytic mechanism. , 1987, Biochemistry.

[50]  M. Gilson Multiple‐site titration and molecular modeling: Two rapid methods for computing energies and forces for ionizable groups in proteins , 1993, Proteins.

[51]  C. Silagy,et al.  Effectiveness and role of zanamivir in the treatment of influenza infection. , 1999, Annals of medicine.

[52]  A. Leo,et al.  Extension of the fragment method to calculate amino acid zwitterion and side chain partition coefficients , 1987, Proteins.

[53]  K. Goa,et al.  Zanamivir , 1999, Drugs.

[54]  P. Andrew Karplus,et al.  Ordered water in macromolecular structure , 1994 .

[55]  L Meijer,et al.  Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition. , 2000, Anti-cancer drug design.

[56]  N R Taylor,et al.  Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B. , 1998, Journal of medicinal chemistry.

[57]  Anna Marabotti,et al.  Free energy of ligand binding to protein: evaluation of the contribution of water molecules by computational methods. , 2004, Current medicinal chemistry.

[58]  R C Wade,et al.  'Flu' and structure-based drug design. , 1997, Structure.

[59]  M. Karplus,et al.  pKa's of ionizable groups in proteins: atomic detail from a continuum electrostatic model. , 1990, Biochemistry.

[60]  Brian J. Smith,et al.  Analysis of inhibitor binding in influenza virus neuraminidase , 2001, Protein science : a publication of the Protein Society.

[61]  G E Kellogg,et al.  Allosteric modifiers of hemoglobin. 2. Crystallographically determined binding sites and hydrophobic binding/interaction analysis of novel hemoglobin oxygen effectors. , 1991, Journal of medicinal chemistry.

[62]  Glen Eugene Kellogg,et al.  Very empirical treatment of solvation and entropy: a force field derived from Log Po/w , 2001, J. Comput. Aided Mol. Des..

[63]  L. J. Bellamy,et al.  Proton transfer in hydrogen bonded systems , 1960, Proceedings of the Royal Society of London. Series A. Mathematical and Physical Sciences.

[64]  K. Sharp,et al.  On the calculation of pKas in proteins , 1993, Proteins.

[65]  J. Hanson,et al.  Potent inhibition of pepsin and penicillopepsin by phosphorus-containing peptide analogues , 1990 .

[66]  P. Kollman,et al.  Biomolecular simulations: recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid noncovalent interactions. , 2001, Annual review of biophysics and biomolecular structure.

[67]  Peter C. Jurs,et al.  Estimation of pKa for organic oxyacids using calculated atomic charges , 1993, J. Comput. Chem..

[68]  M. Itzstein,et al.  Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position , 1993, Glycoconjugate Journal.

[69]  B. Honig,et al.  Classical electrostatics in biology and chemistry. , 1995, Science.

[70]  Arieh Warshel,et al.  Consistent Calculations of pKa's of Ionizable Residues in Proteins: Semi-microscopic and Microscopic Approaches , 1997 .

[71]  S Cusack,et al.  Influenza B virus neuraminidase can synthesize its own inhibitor. , 1993, Structure.

[72]  Zongru Guo,et al.  Study on molecular mechanism and 3D-QSAR of influenza neuraminidase inhibitors. , 2003, Bioorganic & medicinal chemistry.